Testing routes

89 combinations

What to test panelDetail sheet

Curated from pathology practice in src/lib/testing.ts, keyed by biomarker, alteration type and, where practice differs, tumour. Below: every combination that occurs in the data and the route it gets.

ihc Immunohistochemistryeither IHC or molecularmolecular Molecularother Other tests

Biomarker	Alteration	Tumour	Section	How	Rows
AFP	`overexpression`	HCC	Other tests	Serum AFP	1
AKT	`mutation`	Breast	Molecular	DNA sequencing (PIK3CA, AKT1, PTEN)	1
ALK	`wild-type-required`	NSCLC	IHC or molecular	IHC, FISH or RNA-NGS; any one validated method	11
ALK	`fusion`	NSCLC	IHC or molecular	IHC, FISH or RNA-NGS; any one validated method	12
ALK	`fusion`	Other musculoskeletal tumours	IHC or molecular	IHC or FISH	1
ALK	`fusion`	T-cell lymphoma	Immunohistochemistry	IHC (ALK protein)	1
BCR::ABL1	`fusion`	ALL	Molecular	RT-PCR, FISH or karyotype	8
BCR::ABL1	`mutation`	ALL	Molecular	ABL1 kinase domain mutation analysis	1
BCR::ABL1	`fusion`	CML	Molecular	RT-PCR, FISH or karyotype	21
BCR::ABL1	`mutation`	CML	Molecular	ABL1 kinase domain mutation analysis	3
BRAF	`mutation`	CRC	Molecular	DNA sequencing (NGS or PCR)	4
BRAF	`mutation`	Glioma	Molecular	DNA sequencing (NGS or PCR)	5
BRAF	`fusion`	Glioma	Molecular	RNA-NGS or FISH	1
BRAF	`mutation`	Melanoma	Molecular	DNA sequencing (NGS or PCR)	10
BRAF	`mutation`	NSCLC	Molecular	DNA sequencing (NGS or PCR)	4
BRAF	`mutation`	Thyroid	Molecular	DNA sequencing (NGS or PCR)	2
BRCA	`mutation`	Breast	Molecular	Germline testing (blood)	4
BRCA	`mutation`	Ovarian	Molecular	Tumour or germline sequencing	1
BRCA	`mutation`	Pancreatic	Molecular	Germline testing (blood)	1
BRCA	`mutation`	Prostate	Molecular	Tumour or germline sequencing	3
CD19	`overexpression`	ALL	Other tests	Flow cytometry	6
CD20	`overexpression`	B-NHL	Immunohistochemistry	IHC (or flow cytometry)	2
CD20	`overexpression`	LBCL/DLBCL	Immunohistochemistry	IHC (or flow cytometry)	2
CD22	`overexpression`	ALL	Other tests	Flow cytometry	2
CD30	`overexpression`	Hodgkin	Immunohistochemistry	IHC (or flow cytometry)	4
CD30	`overexpression`	T-cell lymphoma	Immunohistochemistry	IHC (or flow cytometry)	1
CD33	`overexpression`	AML	Other tests	Flow cytometry	1
CLDN18.2	`overexpression`	Gastric/GEJ	Immunohistochemistry	IHC; cut-off in SmPC 4.2: ≥ 75% of tumour cells with moderate to strong membrane staining	1
del(5q)	`loss`	MDS	Molecular	Cytogenetics	1
del(5q)	`wild-type-required`	MDS	Molecular	Cytogenetics	1
EBV	`overexpression`	PTLD	Molecular	EBER in situ hybridisation	1
EGFR	`wild-type-required`	NSCLC	Molecular	DNA sequencing (NGS or PCR)	12
EGFR	`mutation`	NSCLC	Molecular	DNA sequencing (NGS or PCR)	19
EpCAM	`overexpression`	Tumour-agnostic	Immunohistochemistry	IHC or cytology	1
ESR1	`mutation`	Breast	Molecular	DNA sequencing, tissue or plasma (ctDNA)	3
FGFR	`fusion`	BTC	Molecular	RNA-NGS or FISH	2
FGFR	`mutation`	Urothelial	Molecular	DNA/RNA sequencing	1
FIP1L1::PDGFRA	`fusion`	MLN-TK	Molecular	FISH (CHIC2 deletion) or RT-PCR	1
FLT3	`mutation`	AML	Molecular	PCR / fragment analysis (ITD and TKD)	7
FRα	`overexpression`	Ovarian	Immunohistochemistry	IHC; cut-off in SmPC 4.2	1
HER2	`overexpression`	Breast	Immunohistochemistry	IHC; ISH if IHC 2+	34
HER2	`overexpression`	Breast	Immunohistochemistry	IHC; ultralow = IHC 0 with membrane staining	1
HER2	`overexpression`	BTC	Immunohistochemistry	IHC; 3+ required	1
HER2	`overexpression`	Gastric/GEJ	Immunohistochemistry	IHC; ISH if IHC 2+	3
HER2	`mutation`	NSCLC	Molecular	DNA sequencing (NGS)	1
HER2	`wild-type-required`	TNBC	Immunohistochemistry	IHC; ISH if IHC 2+	1
HER2	`overexpression`	Tumour-agnostic	Immunohistochemistry	IHC; 3+ required	1
HLA-A*02:01	`overexpression`	Uveal melanoma	Other tests	HLA typing (blood)	1
HR	`overexpression`	Breast	Immunohistochemistry	IHC (ER, PR)	15
HR	`wild-type-required`	TNBC	Immunohistochemistry	IHC (ER, PR)	2
HRD	`signature`	Ovarian	Molecular	Genomic instability (HRD) assay	1
IDH	`mutation`	AML	Molecular	DNA sequencing (NGS or PCR)	1
IDH	`mutation`	BTC	Molecular	DNA sequencing (NGS or PCR)	1
IDH	`mutation`	Glioma	Molecular	DNA sequencing (NGS or PCR)	4
KIT	`overexpression`	GIST	Immunohistochemistry	IHC (CD117)	2
KRAS	`mutation`	NSCLC	Molecular	DNA sequencing (NGS or PCR)	2
MET	`mutation`	NSCLC	Molecular	RNA- or DNA-NGS	2
MMR/MSI	`loss`	BTC	IHC or molecular	MMR IHC (MLH1, PMS2, MSH2, MSH6) or MSI by PCR/NGS	1
MMR/MSI	`loss`	CRC	IHC or molecular	MMR IHC (MLH1, PMS2, MSH2, MSH6) or MSI by PCR/NGS	6
MMR/MSI	`loss`	Endometrial	IHC or molecular	MMR IHC (MLH1, PMS2, MSH2, MSH6) or MSI by PCR/NGS	3
MMR/MSI	`wild-type-required`	Endometrial	IHC or molecular	MMR IHC (MLH1, PMS2, MSH2, MSH6) or MSI by PCR/NGS	2
MMR/MSI	`loss`	Gastric/GEJ	IHC or molecular	MMR IHC (MLH1, PMS2, MSH2, MSH6) or MSI by PCR/NGS	1
MMR/MSI	`loss`	Small intestine	IHC or molecular	MMR IHC (MLH1, PMS2, MSH2, MSH6) or MSI by PCR/NGS	1
NTRK	`fusion`	Tumour-agnostic	IHC or molecular	Pan-TRK IHC to screen; confirm by RNA-NGS	3
PD-L1	`overexpression`	Cervical	Immunohistochemistry	IHC; the scoring system depends on the drug	1
PD-L1	`overexpression`	Gastric/GEJ	Immunohistochemistry	IHC; the scoring system depends on the drug	4
PD-L1	`overexpression`	HNSCC	Immunohistochemistry	IHC; the scoring system depends on the drug	5
PD-L1	`overexpression`	Melanoma	Immunohistochemistry	IHC; the scoring system depends on the drug	1
PD-L1	`overexpression`	NSCLC	Immunohistochemistry	IHC; the scoring system depends on the drug	12
PD-L1	`overexpression`	Oesophageal	Immunohistochemistry	IHC; the scoring system depends on the drug	7
PD-L1	`overexpression`	Ovarian	Immunohistochemistry	IHC; the scoring system depends on the drug	1
PD-L1	`overexpression`	TNBC	Immunohistochemistry	IHC; the scoring system depends on the drug	3
PD-L1	`overexpression`	Urothelial	Immunohistochemistry	IHC; the scoring system depends on the drug	3
PDGFR	`mutation`	GIST	Molecular	DNA sequencing (NGS or PCR)	1
PDGFR	`fusion`	MLN-TK	Molecular	Karyotype, FISH (PDGFRA, PDGFRB) or RNA-NGS	2
PIK3CA	`mutation`	Breast	Molecular	DNA sequencing (NGS or PCR)	3
PML::RARA	`fusion`	AML	Molecular	RT-PCR, FISH or karyotype	4
PSMA	`overexpression`	Prostate	Other tests	PSMA PET imaging	1
RAS	`wild-type-required`	CRC	Molecular	KRAS and NRAS sequencing (exons 2, 3, 4)	6
RET	`wild-type-required`	NSCLC	Molecular	RNA-NGS or FISH	1
RET	`fusion`	NSCLC	Molecular	RNA-NGS or FISH	1
RET	`mutation`	Thyroid	Molecular	DNA sequencing (germline and tumour)	2
RET	`fusion`	Thyroid	Molecular	RNA-NGS or FISH	1
RET	`fusion`	Tumour-agnostic	Molecular	RNA-NGS or FISH	1
ROS1	`fusion`	NSCLC	IHC or molecular	IHC to screen; confirm by FISH or RNA-NGS	3
ROS1	`wild-type-required`	NSCLC	IHC or molecular	IHC to screen; confirm by FISH or RNA-NGS	2
SSTR	`overexpression`	NET	Other tests	Somatostatin receptor imaging	1
TP53	`mutation`	CLL	Molecular	TP53 sequencing and FISH for del(17p)	2
TP53	`wild-type-required`	CLL	Molecular	TP53 sequencing and FISH for del(17p)	2